Small-cell neuroendocrine disease associated with prostate cancer treatment appears to be more common than previously believed.
Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.
Novel Targeted Agents for Lung Cancer: M7824, a Bifunctional Protein Targeting PD-L1 and TGB-β Receptor II
In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.
MSKCC’s Dr. Alexander Drilon highlights other known alterations that are being targeted or being used as biomarkers in non–small-cell lung cancer.
Dr. Hossein Borghaei discusses results of the Checkmate 227 trial and its impact on treatment decision-making in NSCLC.
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.
Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.
USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.